OncRef

Clinical Trial: NCT03581773

Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Niels Fristrup
Information Provided By:University of Aarhus
Last Update Posted:2026-09-23

Study Overview

Brief Summary

FASTERCC: Folic acid supplement versus placebo for treating mucositis adverse events in metastatic renal cell carcinoma patients receiving targeted therapy. A randomized, double-blind trial from the Danish renal cancer group (DARENCA study-4)

Official Title

FASTERCC: Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy. A Randomized, Double-blind Trial From the Danish Renal Cancer Group (DARENCA Study-4)

Conditions

Mucositis, Stomatitis

Intervention / Treatment

  • Drug: Folic Acid
  • Drug: Placebo Oral Tablet

Other Study ID Numbers

  • FASTERCC

Start Date (Actual)

2017-12-20

Primary Completion Date (Actual)

2026-09-22

Study Completion Date (Actual)

2026-09-22

Enrollment (Actual)

84

Study Type

Interventional

Phase

Phase 2